Evidence map›Paper›PMID 29872549›Full record

ArticleNPJ vaccines2018

Yashar Sadigh, Claire Powers, Simon Spiro, Miriam Pedrera, Andrew Broadbent, Venugopal Nair

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yashar Sadigh1The Pirbright Institute, Ash Road, Woking, GU24 0NF United Kingdom.ORCID 0000-0003-1892-1361
Claire Powers1The Pirbright Institute, Ash Road, Woking, GU24 0NF United Kingdom.
Simon Spiro1The Pirbright Institute, Ash Road, Woking, GU24 0NF United Kingdom.
Miriam Pedrera1The Pirbright Institute, Ash Road, Woking, GU24 0NF United Kingdom.
Andrew Broadbent1The Pirbright Institute, Ash Road, Woking, GU24 0NF United Kingdom.
Venugopal Nair1The Pirbright Institute, Ash Road, Woking, GU24 0NF United Kingdom.ORCID 0000-0002-8255-516X
The Pirbright Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K002465/1Biotechnology and Biological Sciences Research Council BBS/E/I/00001029Biotechnology and Biological Sciences Research Council BBS/E/I/00007038Biotechnology and Biological Sciences Research Council BBS/E/I/00007039
6 · The paper itself

Abstract

Live herpesvirus-vectored vaccines are widely used in veterinary medicine to protect against many infectious diseases. In poultry, three strains of herpesvirus vaccines are used against Marek's disease (MD). However, of these, only the herpesvirus of turkeys (HVT) has been successfully developed and used as a recombinant vaccine vector to induce protection against other avian viral diseases such as infectious bursal disease (IBD), Newcastle disease (ND) or avian influenza (AI). Although effective when administered individually, recombinant HVT vectors have limitations when combined in multivalent vaccines. Thus there is a need for developing additional viral vectors that could be combined with HVT in inducing protection against multiple avian diseases in multivalent vaccines.

Identifiers

PMID29872549
PMCPMC5972151
OpenAlexW2805502840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.